BioMarin Pharmaceutical has updated its guidance and filed a shelf registration, alongside reporting second quarter 2026 results. The company's share price stands at US$67.36, with a 90-day return of 35.62% and a 1-year total shareholder return of 17.07%, though the 3-year total shareholder return is down 24.36%. Analysts expect earnings to reach $1.3 billion, or $6.72 per share, by about June 2029, up from $268.7 million today, with estimates ranging from $759.4 million to $2.1 billion. A discounted cash flow analysis using a 7.32% discount rate suggests a fair value of $87.85, implying the stock is 23.3% undervalued.
Biomarin Pharmaceutical IncCompany updates guidance and files shelf registration, with DCF suggesting 23.3% undervaluation.
